Tenofovir AF + Emtricitabine + Bictegravir

Form: Tablet

Strength: Bictegravir-50 mg + Emtricitabine-200 mg + TAF-25 mg

Reference Brands: Biktarvy(EU & US)

Category: Anti Viral

Biktarvy is a complete, once-daily antiretroviral therapy for HIV-1 infection, combining Bictegravir 50 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide (TAF) 25 mg in a single tablet. Approved by both the FDA and EMA, Biktarvy is indicated for adults and pediatric patients (≥2 years, ≥14 kg) who are treatment-naïve or virologically suppressed. Bictegravir, a potent integrase inhibitor, offers a high barrier to resistance and does not require boosting agents. TAF enhances renal and bone safety over older TDF-based regimens. Biktarvy simplifies HIV management, supporting long-term viral suppression and patient adherence through convenient once-daily dosing, with or without food.